Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

13
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

621
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
621
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.5K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

364
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
364
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bioactive Anti-Inflammatory Compounds and Therapeutic Strategies for Promoting Resolution.

Pharmaceutics·2026
Same author

Correction: Mohite et al. Bioactive Compound-Fortified Nanomedicine in the Modulation of Reactive Oxygen Species and Enhancement of the Wound Healing Process: A Review. <i>Pharmaceutics</i> 2025, <i>17</i>, 855.

Pharmaceutics·2026
Same author

Hydrostatic pressure activates HIF-1α via β-catenin to promote stemness in breast cancer cells.

FEBS open bio·2026
Same author

Dapagliflozin Protects Cardiomyocytes against Doxorubicin-Induced Toxicity by Modulating Sirtuin 1/Sirtuin 3 and Ferroptosis Pathway.

ACS pharmacology & translational science·2026
Same author

Damnacanthal Suppresses Breast Cancer Cells by Inducing Apoptosis and Cell Cycle Arrest via NF-ĸB Signaling.

Pharmacology research & perspectives·2026
Same author

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026

Related Experiment Video

Updated: Jul 18, 2025

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
08:47

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Published on: December 16, 2022

2.5K

New Therapeutics for Heart Failure: Focusing on cGMP Signaling.

Supachoke Mangmool1, Ratchanee Duangrat1, Warisara Parichatikanond2

  • 1Department of Pharmacology, Faculty of Science, Mahidol University, Bangkok 10400, Thailand.

International Journal of Molecular Sciences
|August 26, 2023
PubMed
Summary

New heart failure (HF) drugs target cyclic guanosine monophosphate (cGMP) signaling pathways. These novel therapies show promise for both reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF) heart failure.

Keywords:
cyclic guanosine monophosphate (cGMP) signalingdrugsheart failure (HF)natriuretic peptidessoluble guanylyl cyclase (sGC)

More Related Videos

Generation of Aligned Functional Myocardial Tissue Through Microcontact Printing
11:09

Generation of Aligned Functional Myocardial Tissue Through Microcontact Printing

Published on: March 19, 2013

11.2K
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

12.9K

Related Experiment Videos

Last Updated: Jul 18, 2025

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
08:47

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Published on: December 16, 2022

2.5K
Generation of Aligned Functional Myocardial Tissue Through Microcontact Printing
11:09

Generation of Aligned Functional Myocardial Tissue Through Microcontact Printing

Published on: March 19, 2013

11.2K
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

12.9K

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Molecular Biology

Background:

  • Current heart failure (HF) treatments primarily benefit patients with reduced ejection fraction (HFrEF).
  • Novel drug classes are emerging with distinct mechanisms for HF intervention.
  • Cyclic guanosine monophosphate (cGMP) signaling plays a crucial role in myocardial function.

Purpose of the Study:

  • To review the molecular pathways of cGMP signaling in the context of HF.
  • To summarize clinical trials of emerging drug classes targeting cGMP signaling for HF treatment.
  • To highlight the potential of cGMP-targeting drugs for both HFrEF and HFpEF.

Main Methods:

  • Literature review of current and emerging HF therapies.
  • Analysis of molecular mechanisms involving cGMP signaling in the myocardium.
  • Summary of clinical trial data for novel HF drug classes.

Main Results:

  • Emerging drug classes like SGLT2 inhibitors, ARNIs, and sGC modulators show efficacy in HF.
  • SGLT2 inhibitors demonstrate effectiveness in both HFrEF and HFpEF.
  • cGMP signaling pathways offer a promising target for novel HF therapeutics by counteracting detrimental cAMP effects.

Conclusions:

  • Novel drug classes targeting cGMP signaling represent a significant advancement in HF treatment.
  • These therapies hold potential for improving outcomes across the spectrum of HF, including HFpEF.
  • Further research into cGMP pathways may uncover new therapeutic strategies for cardiovascular diseases.